Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Regressin holds promise for a wide range of cancers, new data indicates

July 13, 1998

IL-4 fusion toxin shows potent antitumor activity in murine model of KS

July 10, 1998

NeoPharm scales up IL13-PE38QQR manufacturing

July 10, 1998

GOG will evaluate Avax Technologies' ovarian cancer vaccine in phase I/II study

July 6, 1998

Herceptin licensed to Roche for most markets

July 6, 1998

Phase II retreatment trial with Bexxar commences

June 30, 1998

Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine

June 29, 1998

Orphan drug status granted to Endorex's ImmTher for Ewing's sarcoma

June 29, 1998

CMB-401, an immunoconjugate for the targeted treatment of EOC

June 25, 1998

Positive phase II results for GMK vaccine presented at NCI-EORTC meeting

June 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...